• Explore /
  • Poster
  • / 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

Abstract Poster

Authors

null

Sandra P. D'Angelo

Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY

Sandra P. D'Angelo, Jeffery Scott Russell, Shailender Bhatia, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Celeste Lebbé, Karl D. Lewis, Gerald P. Linette, Michele Milella, Meliessa Hennessy, Marcis Bajars, Isabella Zwiener, Paul Nghiem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT02155647

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 192)

DOI

10.1200/JCO.2018.36.5_suppl.192

Abstract #

192

Poster Bd #

K1

Abstract Disclosures

Similar Posters

First Author: Sandra P. D'Angelo

First Author: Sandra P. D'Angelo

First Author: Astrid Blom Fily

First Author: Jay Oza